Chimeric Antigen Receptor T-Cell Therapy in Dialysis-Dependent Patients With Multiple Myeloma: Insights From a 5-Case Series
Authors:
- Varsha SwamyVSVarsha Swamy
- Kaitlin KellyKKKaitlin Kelly
- Jay L. KoynerJKJay L. Koyner
- Benjamin A. DermanBDBenjamin A. Derman
- Marco BonillaMBMarco Bonilla
Open Access
- 11 October 2025
- journal article
- Published by Elsevier in Kidney Medicine
- Vol. 7 (12)
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
- Amgen
- University of Chicago (IRB24-0901)
This publication has 22 references indexed in Scilit:
- Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 CasesKidney Medicine, 2024
- Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myelomaBlood Cancer Journal, 2023
- Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysisAnnals of Hematology, 2023
- Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisTransplantation and Cellular Therapy, 2022
- Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patientsBone Marrow Transplantation, 2018
- Fludarabine and neurotoxicity in engineered T-cell therapyGene Therapy, 2018
- Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolitesCancer Chemotherapy and Pharmacology, 2015
- Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and PharmacokineticsTransplantation and Cellular Therapy, 2007
- Metabolism and mechanisms of action of bendamustine: Rationales for combination therapiesSeminars in Oncology, 2002
- Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiencyKidney International, 2002